The United States Supreme Court has issued an order preserving the current regulatory framework for the distribution of mifepristone, effectively blocking a lower court's attempt to mandate in-person procurement of the medication.

美國最高法院已發布命令，維持目前 Mifepristone 的配送監管框架，有效地阻止了下級法院要求必須親自領藥的企圖。

The judicial intervention follows a May 1 ruling by the U.S. Court of Appeals for the Fifth Circuit, which had sought to reinstate a requirement for in-person dispensing of mifepristone. This appellate decision was predicated on a lawsuit initiated by the state of Louisiana, which contended that the Food and Drug Administration's (FDA) 2023 policy allowing telehealth prescriptions and mail-order delivery circumvented state-level abortion prohibitions. The state further alleged that such distribution protocols undermined the legal standing of its abortion ban and questioned the pharmacological safety of the drug, despite FDA assertions of its efficacy.

此次司法干預是在美國第五巡迴上訴法院 5 月 1 日的裁決之後，該裁決試圖恢復親自領取 Mifepristone 的要求。此上訴決定是基於路易斯安那州發起的訴訟，該州認為美國食品藥物管理局 (FDA) 2023 年允許遠端醫療處方與郵寄配送的政策，規避了州級的墮胎禁令。該州進一步指稱，此類配送協議削弱了其墮胎禁令的法律地位，並質疑該藥物的藥理安全性，儘管 FDA 斷言其有效。

Within the Supreme Court, the decision to maintain the status quo was met with formal dissents from Justices Clarence Thomas and Samuel Alito. Justice Thomas characterized the operations of the drug manufacturers, Danco Laboratories and GenBioPro, as a 'criminal enterprise,' citing the 1873 Comstock Act—a statute prohibiting the postal transmission of materials intended for abortion. Justice Alito asserted that the FDA's relaxed regulations constituted a strategic effort to undermine the precedent established in Dobbs v. Jackson Women's Health Organization, which devolved the authority to regulate abortion to individual states.

在最高法院內部，維持原狀的決定遭到了大法官 Clarence Thomas 和 Samuel Alito 的正式反對。Thomas 大法官將藥廠 Danco Laboratories 和 GenBioPro 的運作描述為「犯罪企業」，引用了 1873 年的《康斯托克法案》(Comstock Act) —— 一項禁止透過郵政傳送旨在墮胎物質的法令。Alito 大法官則斷言，FDA 放寬監管構成了一種策略性企圖，旨在削弱《多布斯對傑克遜婦女健康組織案》(Dobbs v. Jackson Women's Health Organization) 所建立的先例，該先例將監管墮胎的權限下放至各州。

Institutional implications extend beyond reproductive rights to the broader administrative state. Amicus briefs submitted by pharmaceutical industry representatives and former FDA officials suggested that allowing a single state to override federal drug regulations would destabilize the established scientific approval process. Concurrently, the Trump administration maintained a notable silence, declining to file a brief, a posture interpreted by observers as a strategic avoidance of political friction between anti-abortion constituents and a broader electorate that generally supports abortion access. This internal tension was underscored by the recent resignation of FDA Commissioner Marty Makary following pressure from political allies of the administration.

制度影響不僅限於生殖權利，還延伸至更廣泛的行政國家體系。製藥業代表和前 FDA 官員提交的法庭之友陳述書指出，允許單一州政府推翻聯邦藥物監管將導致既定的科學審批流程失去穩定。與此同時，川普政府保持了顯著的沉默，拒絕提交陳述書，觀察人士將此姿態解釋為策略性地避免反墮胎支持者與普遍支持墮胎權的廣大選民之間產生政治摩擦。FDA 局長 Marty Makary 最近在行政當局政治盟友的壓力下辭職，進一步凸顯了這種內部緊張關係。

Mifepristone remains available through telehealth and mail-order services nationwide while the legal challenge proceeds through the lower courts, with a final resolution likely deferred until at least 2026 or 2027.

在法律挑戰於下級法院進行期間，全美仍可透過遠端醫療與郵寄服務獲取 Mifepristone，最終裁決可能會推遲至至少 2026 或 2027 年。